|
시장보고서
상품코드
2091270
원내감염 치료제 시장 규모, 점유율, 성장 분석 : 약물 계열별, 감염증 적응증별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Hospital Infection Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (Antibacterial Drugs, Antifungal Drugs), By Infection Indication, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 원내감염 치료제 시장 규모는 2024년에 132억 달러로 평가되었으며, 2025년 135억 8,000만 달러에서 2033년까지 170억 6,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 2.89%로 성장할 것으로 전망됩니다.
세계 원내감염 치료제 시장은 디지털 헬스 플랫폼의 통합으로 인해 큰 영향을 받고 있습니다. 이를 통해 병원체의 조기 탐지 및 맞춤형 치료 솔루션을 위한 데이터 기반 모니터링 체계가 강화되고 있습니다. 의료 기록 및 센서를 통한 실시간 분석은 항생제 적정 사용 노력을 지원하고, 부적절한 항생제 사용을 효과적으로 줄이는 동시에 약물 내성을 최소화합니다. 이러한 효율성 향상은 투자자들의 신뢰를 높이고, AI를 활용한 감염 관리 기술에 대한 벤처 캐피털 투자를 촉진하여 시장 확대를 뒷받침하는 한편, 특히 신흥국에서 혁신적인 클라우드 기반 구독 서비스의 보급을 촉진하고 있습니다. 또한, AI를 활용한 자동화를 통해 진단 효율화, 치료 계획의 개별화, 의약품 개발 강화가 이루어지고 있으며, 그 결과 환자의 치료 성과 향상과 자원 효율 개선으로 이어지고 있습니다. 병원들이 데이터 중심 접근 방식을 점점 더 많이 채택함에 따라, 이 시장은 기술 및 의료 서비스 제공의 발전에 힘입어 지속적인 성장이 예상됩니다.
세계 원내감염 치료제 시장의 성장요인
원내감염이 환자의 예후와 의료기관의 평판에 미치는 중대한 영향에 대한 의료 종사자들의 인식이 높아짐에 따라, 선진적인 치료 솔루션 도입으로의 전환이 급속히 진행되고 있습니다. 이러한 인식의 확산은 예방과 치료 양측면에 걸친 투자를 촉진하고 있으며, 병원들이 혁신적인 감염 관리 제품에 자원을 우선적으로 배분하도록 유도하고 있습니다. 그 결과, 의료기관들이 감염 위험을 줄이기 위한 종합적인 전략의 실행에 주력함에 따라, 이 분야의 제조사들에게는 더 광범위한 시장 기회가 열리고 있습니다. 또한, 환자 안전을 중시하는 자세는 규제 기준과도 부합하며, 최첨단 치료법을 임상 현장에 도입하려는 노력이 확고히 자리 잡고 있습니다.
세계 원내감염 치료제 시장의 제약요인
첨단 감염증 치료제는 구조가 복잡하기 때문에 제조 비용이 높게 책정되는 경향이 있으며, 그 결과 의료 서비스 제공자에게는 가격이 급등하게 됩니다. 예산 제약에 직면한 병원은 혁신적인 치료법에 대한 투자와 그 밖의 필수적인 운영상의 필요 사항을 신중하게 비교 검토해야 하며, 그 결과 도입에 대해 보다 신중한 태도를 취하게 됩니다. 이러한 재정적 과제는, 특히 엄격한 상환 체계가 마련된 지역에서 광범위한 도입을 저해하고, 궁극적으로는 시장 침투를 제한할 가능성이 있습니다. 이러한 장벽은 잠재적 성장을 둔화시켜, 성장이 기하급수적인 것보다는 점진적인 양상을 띠게 될 가능성이 있습니다. 그 결과, 의사결정권자들은 비용 대비 효과가 더 높은 해결책을 선호하는 경향이 있어, 가격대가 낮은 검증된 치료법을 선택하는 경우가 많아집니다.
세계 원내감염 치료제 시장의 동향
세계 원내감염 치료제 시장에서는 병원이 첨단 유전체 염기서열 분석 기술을 도입하여 병원체를 실시간으로 모니터링하는 뚜렷한 추세가 나타나고 있습니다. 이러한 접근 방식을 통해 세균 균주를 신속하게 동정할 수 있게 되며, 의료진은 항균 요법을 신속하게 환자별로 맞춤화할 수 있으므로, 광범위 항생제에 대한 의존도를 최소화할 수 있습니다. 병원들이 항생제의 적정 사용을 점점 더 중요시하는 가운데, 이러한 변화는 다제내성균의 증가에 대응하는 데 일조하고 있습니다. 전자 차트와의 연동을 통해 실용적인 알림이 제공되고, 신속한 감염 대책이 촉진되며, 목표가 명확한 위생 관리 프로세스가 확보됨으로써 업무 효율이 향상됩니다. 결국, 이러한 혁신은 환자의 예후를 개선할 뿐만 아니라, 의료 기관 내의 안전 문화를 강화하는 데에도 기여합니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 원내감염 치료제 시장 규모 : 약물 계열별
세계의 원내감염 치료제 시장 규모 : 감염증 적응증별
세계의 원내감염 치료제 시장 규모 : 투여 경로별
세계의 원내감염 치료제 시장 규모 : 유통 채널별
세계의 원내감염 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Hospital Infection Therapeutics Market size was valued at USD 13.2 Billion in 2024 and is poised to grow from USD 13.58 Billion in 2025 to USD 17.06 Billion by 2033, growing at a CAGR of 2.89% during the forecast period (2026-2033).
The global hospital infection therapeutics market is significantly influenced by the integration of digital health platforms, which enhance data-driven surveillance for early pathogen detection and tailored treatment solutions. Real-time analytics from health records and sensors support antimicrobial stewardship efforts, effectively reducing inappropriate antibiotic usage and minimizing resistance. This efficiency cultivates investor confidence and encourages venture capital investment in AI-guided infection-control technologies, facilitating market expansion and promoting innovative cloud-based subscription services, particularly in emerging economies. Furthermore, AI-driven automation streamlines diagnosis, personalizes treatment plans, and enhances drug development, resulting in improved patient outcomes and resource efficiency. As hospitals increasingly adopt data-centric approaches, the market is poised for sustained growth driven by advancements in technology and healthcare delivery.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hospital Infection Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hospital Infection Therapeutics Market Segments Analysis
Global hospital infection therapeutics market is segmented by drug class, infection indication, route of administration, distribution channel and region. Based on drug class, the market is segmented into Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs and Others. Based on infection indication, the market is segmented into Bloodstream Infections, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Infections and Others. Based on route of administration, the market is segmented into Intravenous Formulation, Oral Formulation, Topical Formulation and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hospital Infection Therapeutics Market
The growing awareness among healthcare providers regarding the significant effects of hospital-acquired infections on patient outcomes and institutional reputation is leading to a marked shift towards the adoption of advanced therapeutic solutions. This increased recognition drives investments in both preventive and treatment options, compelling hospitals to prioritize the allocation of resources towards innovative infection-control products. As a result, manufacturers within the sector are presented with broader market opportunities, as healthcare institutions focus on implementing comprehensive strategies to reduce infection risks. Additionally, the emphasis on patient safety aligns with regulatory standards, solidifying the commitment to incorporate state-of-the-art therapies into clinical practices.
Restraints in the Global Hospital Infection Therapeutics Market
The complexity of advanced infection therapeutics often results in significant production costs, leading to high prices for healthcare providers. Hospitals facing budget constraints must carefully weigh their investment in innovative treatments against other essential operational needs, which results in a more cautious approach to adoption. This financial challenge can inhibit widespread implementation, especially in areas with strict reimbursement frameworks, ultimately restricting market penetration. Such barriers can slow down potential growth, making it more incremental than exponential. As a result, decision-makers tend to favor more cost-effective solutions, frequently opting for established therapies with lower price points.
Market Trends of the Global Hospital Infection Therapeutics Market
The Global Hospital Infection Therapeutics market is witnessing a significant trend towards real-time pathogen surveillance, where hospitals integrate advanced genomic sequencing technologies. This approach allows for rapid identification of bacterial strains, enabling healthcare providers to customize antimicrobial therapies swiftly, thereby minimizing reliance on broad-spectrum antibiotics. As hospitals increasingly prioritize antimicrobial stewardship, this shift helps combat the rise of multidrug-resistant organisms. The integration with electronic health records enhances operational efficiency by providing actionable alerts, facilitating prompt infection control measures, and ensuring targeted sanitation processes. Ultimately, these innovations not only improve patient outcomes but also strengthen a culture of safety within healthcare institutions.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Hospital Infection Therapeutics Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Antibacterial Drugs
- Antibiotic Medications
- Other Antibacterials
- Antifungal Drugs
- Antiviral Drugs
- Others
Global Hospital Infection Therapeutics Market Size by Infection Indication & CAGR (2026-2033)
- Market Overview
- Bloodstream Infections
- Hospital-Acquired Pneumonia
- Ventilator-Associated Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Infections
- Others
Global Hospital Infection Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous Formulation
- Oral Formulation
- Topical Formulation
- Others
Global Hospital Infection Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
Global Hospital Infection Therapeutics Market Size & CAGR (2026-2033)
- North America (Drug Class, Infection Indication, Route of Administration, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Infection Indication, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Infection Indication, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Infection Indication, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Infection Indication, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shionogi & Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Basilea Pharmaceutica AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Melinta Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Melinta Therapeutics, LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Theravance Biopharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Spero Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Paratek Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cidara Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Entasis Therapeutics Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sumitomo Pharma Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
